Advanced Cell Technology, Inc. (OTCQB: ACTC) saw its share volume remain strong on June 5th with 10,994,825 shares exchanging hands, slightly higher than its three month daily average volume of 9,875,657 shares.
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today it will host a conference call on Monday, June 9, 2014 at 5:00 p.m. EDT during which ACT will provide an update on clinical and corporate developments.
Among other topics, the following will be discussed during the update call:
- Publication of Mesenchymal Stem Cell study in Stem Cell Reports
- Initiation of myopic macular degeneration trial at Jules Stein Eye Institute at UCLA
- Update on clinical plan for AMD and SMD trials
- Settlement of litigation against the Company
ACTC closed the day at $.068 on June 5th, 10.75% higher than its previous close of $.0614.
PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:
OncoSec Medical Enters Definitive Agreements To Purchase $16 Million Of Securities In A Direct Offering
OncoSec Medical Inc. (OTCQB: ONCS) saw its share volume dip on June 5th with 1,887,244 shares exchanging hands, slightly lower than its three month daily average volume of 2,466,863 shares.
Just this week, OncoSec Medical Inc., a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announced that it has entered into definitive agreements with institutional investors to purchase approximately $16 million of securities in a registered direct offering. OncoSec has agreed to sell to such investors an aggregate of 22,535,212 shares of its common stock at a price of $0.71 per share. Additionally, investors will receive warrants to purchase up to an aggregate of 7,887,325 shares of common stock at an exercise price of $0.90 per share for a term of five years.
The gross proceeds of the offering are approximately $16 million. Net proceeds, after deducting the placement agent’s fee and other estimated offering expenses payable by OncoSec, are expected to be approximately $14.9 million.
The offering is expected to close on or about June 6, 2014, subject to customary closing conditions.
ONCS closed the day at $.7272 on June 5th.
Amarantus Bioscience Sees Share Volume Rise
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) saw its share volume rise on June 5th with 8,234,642 shares exchanging hands, significantly higher than its three month daily average volume of 5,221,193 shares.
Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard").
AMBS closed the day at $.0928 on June 5th, 5.3% lower than its previous close of $.098.
Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.
Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.pennypickalerts.com
Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.